Wohua Pharmaceutical (002107.SZ) released semi-annual results, with net profit of 67.563 million yuan to mother, an increase of 51.23% over the previous year

According to Zhitong Finance App, Wohua Pharmaceutical (002107.SZ) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 393 million yuan, a year-on-year decrease of 7.53%; net profit attributable to shareholders of listed companies was 675.663 million yuan, an increase of 51.23% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 659.59 million yuan, an increase of 54.34% year on year; basic earnings per share were 0.12 yuan. The company plans to distribute a cash dividend of 1.17 yuan (tax included) for every 10 shares to all shareholders.

During the reporting period, the company, under the leadership of the board of directors and executive committee, fully implemented the “detailed, strict and simplified” management requirements, fully implemented the strategic goal of “one reduction and three increases” (i.e. reducing costs and expenses, increasing sales, increasing efficiency, and increasing cash), and continued to promote cost reduction and efficiency, significantly improving efficiency and effectively controlling costs and expenses. Lean production, production costs have been reduced. Continuing to consolidate and expand the hospital market, in-hospital sales revenue from core products is still the “ballast stone” of the company's performance. At the same time, it relies on the brand and academic advantages accumulated in the in-hospital market to achieve accurate extension and efficient coverage to the out-of-hospital market, and construct an “in-hospital+out-of-hospital” collaborative development pattern. Continue to explore the potential of the out-of-hospital market. The results of marketing reforms are increasingly consolidated, and the company's sales team is more professional and mature. The company has adapted to the competitive market trend after major products are collected, while focusing on supporting the development of new potential varieties. Adhere to academic promotion, optimize and adjust the cost structure, combine cost efficiency with cost savings, increase product academic brand building, and continuously unleash product potential. With the “four exclusive health insurance pillar products” as the core engine, we drive the collaborative development of all categories of products, build multi-field and multi-level product clusters, upgrade the growth model from “single point breakthrough” to “multi-point support”, and promote the transformation from “four major varieties” to “variety clusters”. Combining the above factors, the company achieved good results during the reporting period.